Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Quick answer
Tesamorelin is an FDA-approved GHRH analog (Egrifta) proven in large trials to cut visceral fat about 15% in HIV patients. CJC-1295 is an unapproved research peptide with a long half-life but no completed efficacy trial in humans. They share a mechanism but not evidence.
Tesamorelin and CJC-1295 are both synthetic growth-hormone-releasing hormone (GHRH) analogs, but they differ sharply in evidence and legal status. Tesamorelin is FDA-approved (Egrifta) for HIV-associated visceral fat, backed by large human trials. CJC-1295 has no approved human indication and no completed efficacy trial in healthy adults.
CJC-1295 vs Tesamorelin at a glance
| Attribute | CJC-1295 (with DAC) | Tesamorelin (Egrifta) |
|---|---|---|
| Class | Long-acting GHRH analog (research peptide) | GHRH(1-44) analog, FDA-approved drug |
| Mechanism | Stimulates pituitary GH release; DAC binds albumin to extend action | Stimulates pulsatile pituitary GH release |
| Commonly cited research dose | 1–2 mg per week (DAC); "mod GRF 1-29" cited ~100 mcg 1–3×/day | 2 mg (original) or 1.4 mg (Egrifta SV) subcutaneous once daily |
| Half-life | ~5.8–8.1 days (DAC form) (Teichman 2006) | ~26–38 minutes (FDA label) |
| GH/IGF-1 effect | GH up 2–10×; IGF-1 elevated up to ~28 days (single study) | Raises IGF-1; reduces visceral fat ~15% at 26 weeks |
| Best-studied use | None established in humans | HIV-associated lipodystrophy (visceral fat) |
| FDA status | Not approved; 503A Category 2 (PCAC voted against in Dec 2024) | FDA-approved 2010; available by prescription |
| Key risks | Unstudied long-term safety; water retention, IGF-1 elevation | Glucose intolerance/diabetes risk, arthralgia, edema, IGF-1 elevation |
What is the core difference between CJC-1295 and tesamorelin?
The single most important distinction is regulatory and evidentiary. Tesamorelin is a fully FDA-approved prescription drug, marketed as Egrifta and Egrifta SV, approved in 2010 for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy (LiverTox, NIH, 2018; FDA Egrifta label, 2025). Its approval rests on two large Phase 3 randomized, double-blind, placebo-controlled trials enrolling more than 800 patients combined (Falutz et al., NEJM 2007).
CJC-1295 is a research peptide. It has never received FDA approval for any human use, and no completed Phase 3 efficacy trial exists for it in healthy or aging adults. The only published human pharmacokinetic data come from a single early-phase study in 2005–2006 (Teichman et al., J Clin Endocrinol Metab 2006). A Phase 2 trial of CJC-1295 in HIV-associated visceral obesity was halted after a participant death, though the investigating physician attributed the death to pre-existing coronary disease rather than the drug (aidsmap, 2006; ClinicalTrials.gov NCT00267527).
Both molecules belong to the same pharmacologic family — GHRH analogs that prompt the pituitary to release the body's own growth hormone (GH), which in turn raises insulin-like growth factor 1 (IGF-1). But they are not interchangeable, and the depth of evidence behind them is not remotely comparable. For more on this drug class, see our growth hormone peptides overview.
How does CJC-1295 work?
CJC-1295 is a synthetic analog of the first 29 amino acids of GHRH, originally developed by ConjuChem Biotechnologies. The "with DAC" version (the form most often discussed online) carries a Drug Affinity Complex — a maleimidoproprionic acid group that covalently binds to circulating albumin after injection (CJC-1295, PubChem CID 91971820). This albumin binding is what dramatically extends the molecule's lifespan in the bloodstream.
In the only published human study, single subcutaneous doses produced dose-dependent increases in mean plasma GH of 2- to 10-fold lasting six days or more, and increases in mean plasma IGF-1 of 1.5- to 3-fold lasting 9–11 days. After multiple doses, IGF-1 remained above baseline for up to 28 days. The estimated terminal half-life was 5.8 to 8.1 days (Teichman et al., J Clin Endocrinol Metab 2006). That study tested ascending single and multiple doses in healthy adults and reported the compound was generally well tolerated at doses of 30 or 60 mcg/kg.
A critical nuance: "CJC-1295" is frequently confused with "modified GRF (1-29)," sometimes called CJC-1295 without DAC. The version without DAC lacks the albumin-binding tail, so its half-life is closer to 30 minutes rather than days. Research discussions that cite frequent small daily injections (e.g., ~100 mcg, one to three times daily) generally refer to the no-DAC form, while weekly dosing refers to the DAC form. This terminology confusion is one reason CJC-1295 dosing claims online are unreliable. See our CJC-1295 protocol guide for a deeper breakdown.
A defining feature of the DAC form is that its multi-day half-life produces a more continuous elevation in GH, which departs from the body's natural pulsatile rhythm. Notably, one study found GH secretion still retained some pulsatility during continuous CJC-1295 stimulation (Ionescu & Frohman, J Clin Endocrinol Metab 2006). Whether sustained, non-pulsatile GH elevation is desirable or harmful over the long term has not been established in humans.
How does tesamorelin work?
Tesamorelin (trade name Egrifta) is a stabilized analog of human GHRH(1-44). A trans-3-hexenoic acid group is attached to the N-terminus, which protects the peptide from rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) (LiverTox, NIH, 2018). Tesamorelin binds GHRH receptors on somatotroph cells in the anterior pituitary, triggering release of endogenous growth hormone. That GH then stimulates the liver and other tissues to produce IGF-1, the primary mediator of GH's downstream metabolic effects, including lipolysis (fat breakdown) in visceral adipose tissue (FDA Egrifta label, 2025).
Unlike the DAC form of CJC-1295, tesamorelin has a deliberately short half-life — roughly 26 to 38 minutes after subcutaneous injection of a 2 mg dose (FDA Egrifta label, 2025). This short duration is considered a feature, not a limitation: it allows tesamorelin to trigger a discrete GH pulse while preserving the body's natural pulsatile GH secretion pattern, which more closely mimics normal physiology.
The clinical signature of tesamorelin is its selective effect on visceral fat. In the pivotal Phase 3 trial of 412 HIV-positive patients with excess abdominal fat, 26 weeks of daily 2 mg tesamorelin reduced visceral adipose tissue (VAT) by about 15%, while VAT rose roughly 5% in the placebo group — with little change in subcutaneous fat, limb fat, or overall body weight (Falutz et al., NEJM 2007). A separate randomized trial later showed tesamorelin also produced modest reductions in liver fat alongside the visceral fat reduction (Stanley et al., JAMA 2014). For the broader category, see our fat-loss peptides hub.
When should you consider CJC-1295 vs tesamorelin? (decision matrix)
This section describes how the two compounds differ in their research profiles. It is not a recommendation to use either. Any decision about peptides should be made with a licensed healthcare provider.
| Scenario / question | What the evidence points toward |
|---|---|
| You want an FDA-approved, prescribable option with human trial data | Tesamorelin is the only one of the two with FDA approval and large Phase 3 trials (Falutz et al., NEJM 2007). |
| The specific goal is HIV-associated visceral fat | Tesamorelin is the FDA-approved indication; CJC-1295 is not approved for any use (FDA Egrifta label, 2025). |
| You are evaluating long-term human safety data | Tesamorelin has years of trial and post-marketing data; CJC-1295 has only one published human PK study (Teichman et al., 2006). |
| You see claims about "weekly dosing convenience" for CJC-1295 | The DAC form's ~5.8–8.1-day half-life enables weekly dosing, but this convenience is not matched by efficacy evidence (Teichman et al., 2006). |
| You are concerned about blood sugar | Both raise IGF-1; tesamorelin's label specifically warns about glucose intolerance and elevated diabetes risk (FDA Egrifta label, 2025). |
| You want a peptide with a clear legal/compounding pathway | Tesamorelin is a prescription drug; CJC-1295 sits in 503A Category 2 and was voted against by PCAC in December 2024 (FDA 503A bulks process; PeptideClarity regulatory tracker, 2026). |
The honest summary: where there is a head-to-head question, tesamorelin wins on evidence by a wide margin. There is no published trial that directly compares CJC-1295 against tesamorelin in the same population, so any "CJC-1295 is just as good" claim is not supported by direct data.
How do the side effects of CJC-1295 and tesamorelin compare?
Because tesamorelin has been studied in hundreds of patients and CJC-1295 has not, the safety pictures are not symmetric. Tesamorelin's risks are documented in its FDA label; CJC-1295's are largely extrapolated from GHRH-class pharmacology and a single human study. Always discuss any peptide's risk profile with your healthcare provider.
| Side effect / risk | CJC-1295 | Tesamorelin |
|---|---|---|
| Injection-site reactions | Reported in research peptide use | Erythema, pruritus, pain (>5% of patients) (DailyMed, EGRIFTA SV) |
| Joint pain (arthralgia) | Plausible (GH-class effect); not well documented | Common (>5%) (DailyMed, EGRIFTA SV) |
| Fluid retention / peripheral edema | Plausible with GH elevation; anecdotal | Reported (>5%) (DailyMed, EGRIFTA SV) |
| Elevated IGF-1 | Up to ~28 days after dosing (Teichman 2006) | Yes; label requires IGF-1 monitoring (FDA Egrifta label, 2025) |
| Glucose intolerance / diabetes risk | Plausible GH-class effect; not quantified in humans | Documented; ~3.3-fold increased diabetes risk vs placebo (DailyMed, EGRIFTA SV) |
| Contraindications | Not formally defined (unapproved) | Active malignancy, disrupted hypothalamic-pituitary axis, pregnancy, hypersensitivity (DailyMed, EGRIFTA SV) |
| Long-term safety data | None published | Years of trial + post-marketing data |
Both compounds elevate IGF-1, and because IGF-1 has roles in cell proliferation, the tesamorelin label contraindicates use in people with active malignancy and requires IGF-1 monitoring during therapy (FDA Egrifta label, 2025). The label also flags glucose intolerance, advising glucose evaluation before and during treatment (DailyMed, EGRIFTA SV). For CJC-1295, the absence of long-term human data is itself the central safety concern: there simply is not enough published evidence to characterize its risks reliably. Consult your healthcare provider before starting any peptide protocol.
What do CJC-1295 and tesamorelin cost, and can you get them legally?
Tesamorelin is a prescription medication. Brand-name Egrifta and Egrifta SV are notably expensive — historically cited in the range of several thousand dollars per month at retail, with cost heavily dependent on insurance coverage and indication [VERIFY: current Egrifta retail monthly price in 2026]. In New York, tesamorelin requires a prescription from a licensed provider and is dispensed through a pharmacy; it is not legally sold as a "research chemical."
CJC-1295, by contrast, is widely marketed online as a "research-use-only" peptide, typically at far lower nominal prices. That low price reflects its unapproved status, not value: products sold this way are not FDA-reviewed for sterility, identity, or potency, and the FDA has issued recalls of compounded/injectable CJC-1295 over sterility concerns. Buying research peptides for human use carries quality, contamination, and legal risks. See our peptide legal status guide for the full picture.
On the regulatory side, the two diverge sharply. Tesamorelin is an approved drug and is not part of the 503A "bulk drug substances" compounding debate in the way unapproved peptides are. CJC-1295 sits on the FDA's 503A Category 2 list (substances that raise significant safety concerns for compounding), and the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against recommending CJC-1295 for 503A inclusion in December 2024 (PeptideClarity regulatory tracker, 2026). At the upcoming PCAC meeting on July 23–24, 2026, the committee is scheduled to review a different set of peptides (including BPC-157, TB-500, and others) — CJC-1295 is not among them, having already received a negative recommendation (Frier Levitt FDA peptide update, 2026). Legal status varies by jurisdiction; consult a lawyer for binding advice.
Can you stack CJC-1295 and tesamorelin together?
Combining two GHRH analogs is generally redundant rather than synergistic. Both CJC-1295 and tesamorelin act on the same target — the GHRH receptor on pituitary somatotrophs — so stacking them does not add a second mechanism; it simply pushes the same pathway harder, which could amplify shared risks like IGF-1 elevation, fluid retention, and glucose intolerance. There is no published human study evaluating a CJC-1295 plus tesamorelin combination, so any such stack would be entirely unstudied.
A more common (and still unproven for general use) pairing discussed in research contexts combines a GHRH analog with a ghrelin-receptor agonist / GH secretagogue such as ipamorelin, because those act through a complementary pathway. Even so, that is a different conversation from stacking two GHRH analogs against each other. We cover those distinctions in CJC-1295 vs ipamorelin and tesamorelin vs ipamorelin.
Bottom line: there is no evidence-based rationale to combine CJC-1295 and tesamorelin, and doing so would stack their downsides without a documented benefit. Consult your healthcare provider before combining any peptides.
Frequently asked questions
Q: Is tesamorelin better than CJC-1295?
A: For human evidence, yes — clearly. Tesamorelin is FDA-approved and supported by large Phase 3 trials showing roughly a 15% reduction in visceral fat over 26 weeks in HIV patients (Falutz et al., NEJM 2007). CJC-1295 has only one published human pharmacokinetic study and no completed efficacy trial (Teichman et al., 2006). "Better" depends on goals, but tesamorelin is the only one of the two with proven clinical outcomes and regulatory approval. Neither is a substitute for medical guidance.
Q: What is the difference between CJC-1295 and tesamorelin mechanism?
A: Both are GHRH analogs that prompt the pituitary to release growth hormone. The key difference is duration. Tesamorelin has a short half-life (about 26–38 minutes), producing a discrete GH pulse that mimics natural physiology (FDA Egrifta label, 2025). CJC-1295 with DAC binds albumin and has a half-life of roughly 5.8–8.1 days, producing more sustained, less pulsatile GH elevation (Teichman et al., 2006). The molecules also differ structurally — tesamorelin is GHRH(1-44) with an N-terminal modification, while CJC-1295 is based on GHRH(1-29).
Q: Is CJC-1295 FDA approved?
A: No. CJC-1295 is not approved by the FDA for any human use. It is marketed online as a research peptide, sits in 503A Category 2 (significant compounding safety concerns), and the FDA's Pharmacy Compounding Advisory Committee voted against recommending it for the 503A bulks list in December 2024 (PeptideClarity regulatory tracker, 2026). Products sold as "research-use-only" CJC-1295 are not FDA-reviewed for sterility, identity, or potency.
Q: Is tesamorelin used for weight loss?
A: Tesamorelin is FDA-approved specifically to reduce excess visceral (deep abdominal) fat in adults with HIV-associated lipodystrophy — not for general weight loss (FDA Egrifta label, 2025). In trials it selectively reduced visceral fat by about 15% over 26 weeks with little change in total body weight (Falutz et al., NEJM 2007). Off-label or unapproved use for cosmetic weight loss is a medical decision that must be discussed with a licensed provider.
Q: What are the side effects of tesamorelin vs CJC-1295?
A: Tesamorelin's documented side effects include arthralgia, injection-site reactions, peripheral edema, elevated IGF-1, and increased glucose intolerance (about a 3.3-fold higher diabetes risk vs placebo); it is contraindicated in active malignancy and pregnancy (DailyMed, EGRIFTA SV; FDA Egrifta label, 2025). CJC-1295's side effect profile is poorly characterized in humans because only one published human study exists; plausible GH-class effects include water retention and IGF-1 elevation, but long-term safety is unknown (Teichman et al., 2006). Consult your healthcare provider.
Q: Why was a CJC-1295 trial stopped after a death?
A: A Phase 2 study of CJC-1295 in HIV patients with visceral obesity was halted in 2006 after a participant died a few hours after an injection. The attending physician believed the most likely cause was asymptomatic coronary artery disease with plaque rupture, unrelated to the drug, but the trial was terminated as a precaution (aidsmap, 2006; ClinicalTrials.gov NCT00267527). The event has not been established as drug-caused, but it is part of why CJC-1295's human safety record remains thin.
Q: Can you take CJC-1295 and tesamorelin together?
A: There is no published human study on combining them, and because both act on the same GHRH receptor, stacking is redundant rather than synergistic — it would likely amplify shared risks (IGF-1 elevation, fluid retention, glucose intolerance) without a documented added benefit. Any combination should only be considered under direct medical supervision. Consult your healthcare provider before combining any peptides.
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18046027. https://pubmed.ncbi.nlm.nih.gov/18046027/
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMC4363137. https://pmc.ncbi.nlm.nih.gov/articles/PMC4363137/
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- U.S. Food and Drug Administration. EGRIFTA SV (tesamorelin for injection) Full Prescribing Information. 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505
- DailyMed (U.S. National Library of Medicine). EGRIFTA SV — tesamorelin kit label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Tesamorelin. National Institute of Diabetes and Digestive and Kidney Diseases; 2018. NBK548730. https://www.ncbi.nlm.nih.gov/books/NBK548730/
- ClinicalTrials.gov. A Study to Evaluate CJC-1295 in HIV Patients With Visceral Obesity. NCT00267527. https://clinicaltrials.gov/study/NCT00267527
- aidsmap. Lipodystrophy study (CJC-1295) halted after patient death. July 2006. https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death
- National Center for Biotechnology Information. CJC-1295, PubChem Compound Summary CID 91971820. https://pubchem.ncbi.nlm.nih.gov/compound/91971820
- Frier Levitt. FDA Peptide Update 2026: Removal from "Do Not Compound" List and PCAC July 2026 review. 2026. https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/
- PeptideClarity. Peptide FDA Regulatory Tracker: PCAC, 503A/503B Status (CJC-1295 December 2024 PCAC vote). 2026. https://getpeptideclarity.com/regulatory
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.